Hyperosmolar hyperglycemic state pathophysiology: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Hyperosmolar hyperglycemic state}} {{CMG}}; {{AE}} ==Overview== The exact pathogenesis of [disease name] is not fully understood. OR It is thought that [diseas..." |
|||
| Line 32: | Line 32: | ||
==Pathophysiology== | ==Pathophysiology== | ||
===Glucose homeostasis=== | |||
====Anabolic state during meals==== | |||
*During fed state, high glycemic levels cause increased insulin release from pancreatic beta cells. | |||
*Increased insulin levels inhibit glucagon from pancreatic alpha cells which lead to increase insulin to glucagon ratio. | |||
*High insulin-to-glucagon ratio favors anabolic state during which insulin mediated uptake of glucose occurs in liver and muscle which is stored as glycogen. | |||
*Insulin dependent uptake of glucose also drives potassium into the cells. | |||
*The high insulin-to-glucagon ratio also favors uptake of amino acids by muscle. | |||
====Catabolic state between meals==== | |||
*Between meals, the decrease in insulin and rise in glucagon leads to low plasma insulin-to-glucagon ratio which favors the catabolic state. | |||
*During catabolic state, the breakdown of glycogen in the liver and muscle and gluconeogenesis by the liver occurs. | |||
*Both these processes maintain plasma glucose concentration in the normal range. | |||
*The low insulin-to-glucagon ratio also favors lipolysis and ketone body formation. | |||
*Several insulin-independent tissues like brain and the kidney use glucose regardless of the insulin-to-glucagon ratio. | |||
===Pathogenesis=== | ===Pathogenesis=== | ||
The progression to hyperosmolar hyperglycemic state (HHS) can occur due to the reduction in the net effective concentration of insulin relative to glucagon and other counterregulatory stress hormones (catecholamines, cortisol, and growth hormone), which can be seen in a multitude of settings. | |||
*In type 1 diabetics, there is an immune-associated destruction of insulin-producing pancreatic β cells, which leads to no or decreased levels of insulin in the body. | |||
*In type 2 diabetics, although the major mechanism of hyperglycemia is peripheral insulin resistance and there is some basal production of insulin; patients may develop a failure of pancreatic β cells at late stages of the disease. | |||
* | *The levels of counterregulatory stress hormones can increase during an acute illness (eg, genitourinary or pulmonary infections, myocardial infarction [MI], or pancreatitis) or stress (eg, surgery) or when counterregulatory hormones are given as therapy (eg, dexamethasone), and as a result of their overproduction (eg, in Cushing syndrome). | ||
* | *Some pharmacologic agents (notably, antipsychotics like clozapine, olanzapine, risperidone and immunosuppressive agents, such as cyclosporine or other medications including interferon, pentamidine, sympathomimetic agents like albuterol, dobutamine, terbutaline, can also cause insulin resistance. | ||
* | *All these situations can cause decrease effective insulin-to-glucagon ratio which can lead to the hyperosmolar hyperglycemic state. | ||
* | ====Hyperglycemia==== | ||
* | ====Hyperosmolarity==== | ||
==Genetics== | ==Genetics== | ||
Revision as of 16:31, 22 August 2017
|
Hyperosmolar hyperglycemic state Microchapters |
|
Differentiating Hyperosmolar hyperglycemic state from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hyperosmolar hyperglycemic state pathophysiology On the Web |
|
American Roentgen Ray Society Images of Hyperosmolar hyperglycemic state pathophysiology |
|
Hyperosmolar hyperglycemic state pathophysiology in the news |
|
Risk calculators and risk factors for Hyperosmolar hyperglycemic state pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
The exact pathogenesis of [disease name] is not fully understood.
OR
It is thought that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].
OR
[Pathogen name] is usually transmitted via the [transmission route] route to the human host.
OR
Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.
OR
[Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].
OR
The progression to [disease name] usually involves the [molecular pathway].
OR
The pathophysiology of [disease/malignancy] depends on the histological subtype.
Pathophysiology
Glucose homeostasis
Anabolic state during meals
- During fed state, high glycemic levels cause increased insulin release from pancreatic beta cells.
- Increased insulin levels inhibit glucagon from pancreatic alpha cells which lead to increase insulin to glucagon ratio.
- High insulin-to-glucagon ratio favors anabolic state during which insulin mediated uptake of glucose occurs in liver and muscle which is stored as glycogen.
- Insulin dependent uptake of glucose also drives potassium into the cells.
- The high insulin-to-glucagon ratio also favors uptake of amino acids by muscle.
Catabolic state between meals
- Between meals, the decrease in insulin and rise in glucagon leads to low plasma insulin-to-glucagon ratio which favors the catabolic state.
- During catabolic state, the breakdown of glycogen in the liver and muscle and gluconeogenesis by the liver occurs.
- Both these processes maintain plasma glucose concentration in the normal range.
- The low insulin-to-glucagon ratio also favors lipolysis and ketone body formation.
- Several insulin-independent tissues like brain and the kidney use glucose regardless of the insulin-to-glucagon ratio.
Pathogenesis
The progression to hyperosmolar hyperglycemic state (HHS) can occur due to the reduction in the net effective concentration of insulin relative to glucagon and other counterregulatory stress hormones (catecholamines, cortisol, and growth hormone), which can be seen in a multitude of settings.
- In type 1 diabetics, there is an immune-associated destruction of insulin-producing pancreatic β cells, which leads to no or decreased levels of insulin in the body.
- In type 2 diabetics, although the major mechanism of hyperglycemia is peripheral insulin resistance and there is some basal production of insulin; patients may develop a failure of pancreatic β cells at late stages of the disease.
- The levels of counterregulatory stress hormones can increase during an acute illness (eg, genitourinary or pulmonary infections, myocardial infarction [MI], or pancreatitis) or stress (eg, surgery) or when counterregulatory hormones are given as therapy (eg, dexamethasone), and as a result of their overproduction (eg, in Cushing syndrome).
- Some pharmacologic agents (notably, antipsychotics like clozapine, olanzapine, risperidone and immunosuppressive agents, such as cyclosporine or other medications including interferon, pentamidine, sympathomimetic agents like albuterol, dobutamine, terbutaline, can also cause insulin resistance.
- All these situations can cause decrease effective insulin-to-glucagon ratio which can lead to the hyperosmolar hyperglycemic state.
Hyperglycemia
Hyperosmolarity
Genetics
- [Disease name] is transmitted in [mode of genetic transmission] pattern.
- Genes involved in the pathogenesis of [disease name] include [gene1], [gene2], and [gene3].
- The development of [disease name] is the result of multiple genetic mutations.
Associated Conditions
Gross Pathology
- On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
Microscopic Pathology
- On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].